Compare KARO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | HRMY |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2020 | 2020 |
| Metric | KARO | HRMY |
|---|---|---|
| Price | $63.97 | $34.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $74.41 | $48.08 |
| AVG Volume (30 Days) | 50.5K | ★ 1.1M |
| Earning Date | 10-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.63 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $20.98 | $18.39 |
| Revenue Next Year | $16.26 | $14.19 |
| P/E Ratio | $24.13 | ★ $12.80 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $41.25 | $25.90 |
| 52 Week High | $68.80 | $43.49 |
| Indicator | KARO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 37.51 |
| Support Level | $63.03 | $33.49 |
| Resistance Level | $67.54 | $35.47 |
| Average True Range (ATR) | 2.01 | 1.58 |
| MACD | -0.06 | -0.32 |
| Stochastic Oscillator | 47.12 | 26.84 |
Karooooo Ltd is a provider of an operational intelligence platform. Through its cloud platform, the company enables fleet and asset management, fuel management, workforce management, logistics, safety, including AI-assisted video safety, compliance, risk, and environmental impact management. Its segments are: Cartrack, which generates the majority of revenue, provides an operational intelligence platform that maximizes the value of transportation, operations, and workflow data through insightful real-time data analytics to connected vehicles and equipment, and Karooooo Logistics provides a software application enabling the management of last-mile B2B delivery and general operational logistics (Delivery-as-a-Service or DaaS). It generates the majority of its revenue from South Africa.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.